Gillespie, L. , Jr.: Clinical pharmacology of newer antihypertensive agents, monoamine oxidase and decarboxylase inhibitors, Bretylium Tosylate and Guanethidine. Ann. New York Acad. Sc., 88: 1011, 1960.
2.
Cannon, P.J., Whitlock, R.T., and Laragh, J.H.: Panel discussion: alpha methyl dopa in hypertension. In VII International Congress of Internal Medicine, Summaries, p. 121,1962.
3.
Hamilton, M. , and Kopelman, H.: Treatment of severe hypertension. Brit. Med. J., 1: 151, 1963.
4.
Doyle, A.: Panel discussion: alpha methyl dopa in hypertension. In VII International Congress of Internal Medicine, Summaries, p. 120, 1962.
5.
Dollery, C.T. , and Harington, M.: Methyl dopa in hypertension. Lancet, 1: 759, 1962.
6.
Gillespie, L. , Jr., Oates, J.A., Crout, J.R., and Sjoerdsma , A.: Clinical and chemical studies with alpha methyl dopa in patients with hypertension. Circulation, 25: 281, 1962.
7.
Cannon, P.J. , Whitlock, R.T., Morris, R.C., Angers, M., and Laragh, J.H.: Alpha methyl dopa in malignant hypertension . J.A.M.A., 179: 673, 1962.
8.
Sannerstedt, R., Varnauskas, E., and Werko, L.: Hemodynamic efforts of methyldopa at rest and during exercise in patients with arterial hypertension. Acta med. scandinav., 171: 75, 1962.
9.
North, G.D.K.: Panel discussion: alpha methyl dopa in hypertension. In VII International Congress of Internal Medicine, Summaries, p. 124, 1962.
10.
Kobayashi, T. : Panel discussion: alpha methyl dopa in hypertension . In VII International Congress of Internal Medicine, Summaries, p. 123, 1962.
11.
Sannerstedt, R., and Werko, L.: Hemodynamic aspects of modern medical treatment of arterial hypertension. Med. Clin. NorthAmerica, 46: 1639, 1962.
